CXCL2 and neoplasm: Modulation of oral commensal bacteria and immune mediators such as IL-17–producing γδ T cells or CXCL2/CXCR2 could aid in monitoring OSCC progression and in developing adjunct therapies to mitigate tumor-promoting inflammation [76, 78, 121].